Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
22.84
+0.48 (2.15%)
Jan 21, 2025, 4:00 PM EST - Market closed
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $168.57M in the quarter ending September 30, 2024, with 2.83% growth. This brings the company's revenue in the last twelve months to $694.96M, up 4.40% year-over-year. In the year 2023, Pacira BioSciences had annual revenue of $674.98M with 1.22% growth.
Revenue (ttm)
$694.96M
Revenue Growth
+4.40%
P/S Ratio
1.52
Revenue / Employee
$976,063
Employees
712
Market Cap
1.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
PCRX News
- 11 hours ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit – PCRX - GlobeNewsWire
- 12 hours ago - The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Pacira BioSciences, Inc. - Accesswire
- 1 day ago - Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm - Accesswire
- 1 day ago - Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PCRX - PRNewsWire
- 5 days ago - Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm - Accesswire
- 5 days ago - Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX - PRNewsWire
- 6 days ago - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - PRNewsWire
- 6 days ago - The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Pacira BioSciences Inc - Accesswire